First AD

Second AD

Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

Video content above is prompted by the following:

What are some of the newer, nonstatin LLTs that are approved for lowering LDL-Cand reducing CVD risk (eg, inclisiran, alirocumab, evolocumab, bempedoic acid)?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

From LDL-C to Lp(a): A Multispecialty Approach to Reducing the Rising Tide of Cardiovascular Disease

Pediatric lipid screening is crucial for early detection and management of dyslipidemia, which can prevent cardiovascular diseases later in life. Current guidelines recommend universal lipid screening for children between ages 9-11 and 17-21, with selective screening for those with risk factors. However, implementation remains inconsistent due to barriers such as lack of awareness and time constraints in clinical practice. To improve uptake, strategies include integrating screening into routine pediatric visits, utilizing electronic health records for reminders, and educating healthcare providers and families about the importance and benefits of early lipid screening.

Panelists discuss how newer nonstatin therapies, such as PCSK9 inhibitors (inclisiran, alirocumab, evolocumab) and bempedoic acid, offer additional options for LDL-C reduction and cardiovascular risk management.

Prevalence of Cardiovascular Disease